Published in Clinical Oncology Week, March 15th, 2010
"CyDex's Captisol technology improves the solubility and stability of a number of active pharmaceutical ingredients, and continues to be licensed by major pharmaceutical companies for a variety of therapies," said Odlaug. "In addition, we strengthened our patent portfolio and made significant advances in drug development during the past year, including completing an early proof-of-concept phase II clinical trial for a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.